Role of dopamine receptor agonists in the treatment of early Parkinson's disease (Q37685682)

22 August 2017

1 reference

title

Role of dopamine receptor agonists in the treatment of early Parkinson's disease (English)

1 reference

22 August 2017

0 references

1 reference

Olivier Rascol

1 reference

ORCID Public Data File 2021

22 August 2017

Ubaldo Bonuccelli

1 reference

author name string

Paolo Del Dotto

series ordinal

1 reference

22 August 2017

publication date

1 December 2009

1 reference

Parkinsonism and Related Disorders

22 August 2017

published in

1 reference

22 August 2017

volume

15 Suppl 4

1 reference

22 August 2017

page(s)

S44-53

1 reference

Treatment of parkinsonism with bromocriptine.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pergolide: long-term use in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Dopamine agonist therapy in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A novel dopamine agonist for the transdermal treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Dopamine agonists: their role in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Bromocriptine and the clinical spectrum of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pramipexole in patients with early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A controlled trial of rotigotine monotherapy in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Long-term treatment of Parkinson's disease with bromocriptine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Treatment of Parkinson's disease should begin with a dopamine agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Fibrosis associated with dopamine agonist therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Valvular heart disease in patients taking pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Dopamine agonists and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Sleep episodes in Parkinson's disease: a wake-up call

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Dopamine agonists and sleep in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Predictors of sudden onset of sleep in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Sudden uncontrollable somnolence and medication use in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pathological gambling caused by drugs used to treat Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Problematic gambling on dopamine agonists: Not such a rarity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Pathological gambling secondary to dopaminergic therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Prevalence of pathological gambling in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970835-1

7 January 2021

10.1016/S1353-8020(09)70835-1

Identifiers

DOI

1 reference

22 August 2017

1 reference